Ovide is a drug owned by Taro Pharmaceutical Industries Ltd. It is protected by 2 US drug patents filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 01, 2027. Details of Ovide's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7560445 | Process for preparing malathion for pharmaceutical use |
Feb, 2027
(1 year, 8 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7977324 | Process for preparing malathion for pharmaceutical use |
Aug, 2026
(1 year, 2 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ovide's patents.
Latest Legal Activities on Ovide's Patents
Given below is the list of recent legal activities going on the following patents of Ovide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Jan, 2023 | US7977324 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jan, 2021 | US7560445 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Nov, 2018 | US7977324 |
| Change in Power of Attorney (May Include Associate POA) Critical | 09 Mar, 2017 | US7977324 |
| Email Notification Critical | 09 Mar, 2017 | US7977324 |
| Correspondence Address Change Critical | 07 Mar, 2017 | US7977324 |
| Email Notification Critical | 23 Feb, 2017 | US7560445 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 23 Feb, 2017 | US7560445 (Litigated) |
| Correspondence Address Change Critical | 21 Feb, 2017 | US7560445 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 04 Sep, 2012 | US7977324 |
US patents provide insights into the exclusivity only within the United States, but Ovide is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ovide's family patents as well as insights into ongoing legal events on those patents.
Ovide's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ovide's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 01, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ovide Generic API suppliers:
Malathion is the generic name for the brand Ovide. 2 different companies have already filed for the generic of Ovide, with Norvium Bioscience having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ovide's generic
How can I launch a generic of Ovide before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Ovide's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Ovide's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Ovide -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.005 | 16 Mar, 2011 | 1 | 23 May, 2012 | 01 Feb, 2027 | Deferred |
About Ovide
Ovide is a drug owned by Taro Pharmaceutical Industries Ltd. It is used for treating head lice and their eggs on the scalp hair. Ovide uses Malathion as an active ingredient. Ovide was launched by Taro in 1982.
Approval Date:
Ovide was approved by FDA for market use on 02 August, 1982.
Active Ingredient:
Ovide uses Malathion as the active ingredient. Check out other Drugs and Companies using Malathion ingredient
Treatment:
Ovide is used for treating head lice and their eggs on the scalp hair.
Dosage:
Ovide is available in lotion form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | LOTION | Discontinued | TOPICAL |